← Markets

CVS Health Corp.

CVS · NYSE

Market closed$107.47$0.970000 (+0.91%)After hours $107.60 · +0.12%

Key statistics

Previous close$106.50
Open$106.70
Day high$108.96
Day low$106.61
52-week high$108.96
52-week low$58.50
Market cap137.12B
Volume6.61M
Average volume8.31M
P/E ratio15.20
Forward P/E8.95
EPS7.07
Dividend yield+2.48%

Market context

Why it moved

CVS Health shares edged higher, supported by Wells Fargo raising its price target to $123 with an "overweight" rating and positive analyst sentiment ahead of the company's upcoming earnings release, where it is expected to beat consensus estimates.

MarketbeatYahoo FinanceLa CriticalmassHallrenderYahoo Finance

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026CVS Health shares closed modestly higher, touching a new 52-week high of $108.96 intraday, lifted by sector-wide optimism after UnitedHealth Group's massive Q2 earnings beat and raised guidance improved sentiment across managed-care stocks. Adding to the bullish backdrop, Truist issued a new $118 price target, and analysts at RBC Capital and Cantor Fitzgerald recently set targets of $113 and $110, respectively — all above the current consensus of ~$105. The company also opened its first pharmacy-focused Houston location and continues to benefit from resolution of FTC litigation via its CVS Caremark settlement, removing a key regulatory overhang.

0.9108

July 17, 2026CVS Health edged higher, touching a new 52-week high intraday, as a blowout Q2 earnings report from sector bellwether UnitedHealth Group lifted managed care stocks broadly. UNH surged after posting adjusted EPS of $6.38 vs. estimates of $4.90 and raising its full-year outlook, with a medical cost ratio of 86.7% well below expectations — easing industry-wide concerns about elevated healthcare utilization. CVS also benefits from its own positive momentum: Q1 2026 adjusted EPS of $2.57 beat estimates by $0.36, full-year guidance was raised to $7.30–$7.50, and Aetna's Health Care Benefits segment showed meaningful margin recovery. Multiple analysts have lifted price targets, with Wells Fargo, Truist, and Mizuho setting targets of $123, $118, and $115 respectively. A recent FTC settlement with CVS Caremark over drug rebates and TrumpRx integration adds regulatory clarity, while ongoing legislative efforts to restrict PBM-insurer conglomerates remain a longer-term overhang to watch.

0.5571

July 16, 2026CVS Health closed essentially flat as investors digested a major FTC settlement by its Caremark PBM unit, which the company framed positively as resolving all outstanding litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration — with the FTC estimating up to $13 billion in potential consumer savings. The stock, trading near its 52-week high, also faces crosscurrents from sector headwinds: peer Elevance Health's underwhelming full-year guidance disappointed investors despite a Q2 beat, while HCA Healthcare cut its 2026 earnings forecast on rising uninsured patients. These pressures weighed on the broader XLV healthcare ETF, though CVS remains well-supported by strong Q1 results (EPS of $2.57 vs. $2.21 estimate) and raised FY2026 guidance of $7.30–$7.50 EPS.

-0.2543

July 15, 2026CVS Health closed modestly higher, touching a new 52-week high of $106.90 intraday, as two major developments captured investor attention. CVS Caremark announced a global settlement with the FTC resolving all outstanding litigation related to rebate, pharmacy network contracting, and vertical integration issues — a significant regulatory overhang lifted — with Goldman Sachs and Truist both raising price targets to $116 and $118, respectively. Countering the positive tone, CVS's Aetna unit was named in an expanding DOJ antitrust probe into Claritev over alleged conspiracies to suppress out-of-network reimbursements, adding a fresh legal cloud even as the broader healthcare sector faced pressure from HCA Healthcare's profit warning tied to rising uninsured volumes from ACA exchange turmoil.

0.2644

July 14, 2026CVS Health shares gained, touching a fresh 52-week high of $106.39, outperforming the healthcare sector (XLV) as Wells Fargo raised its price target to $123 from $103 while maintaining an Overweight rating — a significant vote of confidence above the current consensus target of ~$102.84. The move builds on momentum from CVS's strong Q1 beat and raised FY2026 EPS guidance of $7.30–$7.50, with Q2 earnings due August 5 and analysts expecting continued improvement in medical cost trends at Aetna. Investors are also balancing positive catalysts — including a $0.665 quarterly dividend and positioning as a managed-care consolidation beneficiary — against legal overhangs from a $440M DOJ billing settlement and ongoing state/federal legislative efforts to restrict integrated insurer-pharmacy models.

1.6803

July 11, 2026CVS Health rose modestly, approaching its 52-week high near $106, as bullish sentiment builds ahead of its August 5 Q2 earnings report. The CEO's comments that Aetna has medical costs 'under control' are bolstering investor confidence in margin recovery, while Jim Cramer's endorsement of CVS as a top managed care winner amid Walgreens' retreat added momentum. Offsetting factors include a $440M DOJ Omnicare settlement, a $36.5M multistate insulin overbilling settlement, and legislative efforts in multiple states to break up pharmacy-insurance conglomerates.

1.3034

July 10, 2026CVS Health closed down nearly 1.6%, pressured by a $36.5 million multistate insulin overbilling settlement and ongoing legislative scrutiny targeting the company's integrated pharmacy-insurance model. The settlement, coordinated with the DOJ and 36 state attorneys general, requires CVS to admit responsibility for improper Medicaid reimbursements. Separately, lawmakers in multiple states are advancing measures to restrict large insurers from controlling pharmacy benefit management, with CVS already in federal court fighting a Tennessee law. Offsetting some headwinds, CEO David Joyner offered investors pre-Q2 assurances that Aetna has medical costs under control, RBC Capital raised its price target to $113 (Outperform), and Jim Cramer highlighted CVS as a managed care winner.

-1.589

July 9, 2026CVS Health closed essentially flat amid a broad market risk-off session triggered by renewed U.S.-Iran tensions, with shares hovering near their 52-week high of $106.15 — a level that has become a key test for the stock's ongoing rally. The healthcare sector provided relative shelter, with XLV outperforming as investors rotated away from tech and cyclicals. Underpinning CVS's resilience are strong Q1 fundamentals — a $0.36 EPS beat and raised FY2026 guidance of $7.30–$7.50 — alongside a wave of analyst upgrades from Morgan Stanley ($111 target), Mizuho ($115), and Piper Sandler ($113). However, emerging headwinds include state-level legislative efforts in Arkansas and Tennessee to break up pharmacy benefit manager and retail pharmacy operations, against which CVS has already filed a federal lawsuit, as well as a product recall and notable insider selling.

0.1342

Politico · July 16, 2026CVS Health floats cost solutionsReuters · July 14, 2026CVS settles with FTC, agrees to count TrumpRx drug purchases towards insuranceHealthcare Dive · July 14, 2026CVS Caremark reaches settlement with FTC over insulin suitSeeking Alpha · May 5, 2026CVS earnings in focus as investors watch cost trends, margins (CVS:NYSE)24/7 Wall St. · February 10, 2026The CVS Earnings Bombshell That Has Investors Scrambling Right NowPR Newswire · December 9, 2025CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event
Mt Newswire · July 17, 2026CVS Health Opens Pharmacy-Focused Location in Houston
Benzinga · July 15, 2026FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
Mt Newswire · July 14, 2026CVS Caremark Reaches Settlement With FTC to Deliver Affordable Prescription Medicine
Mt Newswire · July 14, 2026Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
Benzinga · July 14, 2026CVS Health's CVS Caremark Announces Settlement With U.S. Federal Trade Commission To Resolve All Outstanding Litigation, Probe
Mt Newswire · July 14, 2026Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
Mt Newswire · July 14, 2026Market Chatter: DOJ Expands Antitrust Probe Into Claritev
Benzinga · July 14, 2026Truist Securities Maintains Buy on CVS Health, Raises Price Target to $118

Peers

S&P 500SPX · $7,457.78-1.01%UnitedHealth Group IncorporatedUNH · $426.09+0.64%Cigna CorporationCI · $281.45-0.84%Elevance Health Inc.ELV · $373.11+0.07%Humana Inc.HUM · $400.00+3.50%Cardinal Health, Inc.CAH · $228.52-0.09%Centene Corp.CNC · $66.44+3.99%Quest Diagnostics IncorporatedDGX · $210.68+0.61%Labcorp Holdings Inc.LH · $283.36+0.50%Molina Healthcare, Inc.MOH · $225.37+0.24%Walmart Inc.WMT · $114.24-0.62%Amazon.com, Inc.AMZN · $247.23-1.06%